Today: 9 June 2026
Analog Devices stock slips as year-end tech dip cools semis; what investors watch next
31 December 2025
1 min read

Analog Devices stock slips as year-end tech dip cools semis; what investors watch next

NEW YORK, December 30, 2025, 22:49 ET — Market closed.

  • Analog Devices closed down 0.3% at $274.82.
  • U.S. indexes edged lower in holiday-thinned trading as tech weighed, with investors parsing fresh Fed minutes.
  • Attention shifts to Wednesday’s session and ADI’s next earnings update, currently pegged for mid-February on calendars.

Analog Devices (ADI) shares slipped on Tuesday, ending down 0.3% at $274.82 as chip stocks drifted lower into the final stretch of the year.

The move matters because liquidity is thin in the holiday-truncated week, which can amplify relatively small shifts in positioning across semiconductors and other growth-linked stocks.

Investors also digested minutes from the U.S. Federal Reserve’s December meeting, keeping interest-rate expectations in focus for rate-sensitive technology shares.

ADI traded between $274.59 and $277.10 during the session after opening at $276.70, market data showed.

The iShares Semiconductor ETF (SOXX) was down about 0.1% on the day. Analog chip peer Texas Instruments eased, while NXP Semiconductors slipped and Microchip Technology edged higher.

Wall Street finished slightly lower overall, with technology and financial shares weighing on major indexes in choppy trading, Reuters reported.

“It’s just a healthy rebalancing of allocations more so than an emotionally driven sell-off (in tech),” said Mark Hackett, chief market strategist at Nationwide. Reuters

The Fed next meets on Jan. 27-28, and investors were expecting policymakers to leave rates unchanged, Reuters reported.

For ADI, the latest company catalyst remains its late-November results and outlook, when the company forecast fiscal first-quarter revenue of about $3.1 billion, plus or minus $100 million, and adjusted profit of $2.29 per share, plus or minus 10 cents.

CFO Richard Puccio said then that bookings were holding up, with industrial — nearly half of ADI’s revenue — supported by infrastructure spending themes such as factory automation, defense, healthcare and energy, Reuters reported.

Before Wednesday’s session, traders will watch whether thin year-end conditions keep price action jumpy, especially in semiconductor names that have been sensitive to shifts in rate expectations.

ADI’s next major checkpoint is its quarterly report. Nasdaq’s earnings calendar currently points to Feb. 18, 2026, though the company has not confirmed a date; investors will be looking for updates on industrial and automotive demand and any change to management’s fiscal first-quarter stance.

On the chart, ADI has swung sharply this month, from an intraday low of $262.00 on Dec. 1 to a high of $284.23 on Dec. 12. Those recent extremes are levels technical traders often keep on watch heading into year-end and the new year.

Stock Market Today

  • Aker BP Share Price Surges Amid Valuation Debate
    June 9, 2026, 11:54 AM EDT. Aker BP (OB:AKRBP) shares climbed to NOK347.7, marking a 55.05% total shareholder return over one year, outperforming peers in Norway's energy sector. Despite this momentum, the stock trades at an 8.6% premium over a fair value of NOK320.11, raising questions about valuation. The company aims to sustain production above 500,000 barrels per day past 2030, backed by projects like Yggdrasil and Johan Sverdrup, supporting revenue growth. Yet, potential risks include higher emissions costs and delays in key developments. Analysts offer cautious pricing, but a discounted cash flow (DCF) model from Simply Wall St suggests a much higher intrinsic value of NOK1,769.75, indicating significant undervaluation. Investors face a valuation divide between conservative targets and optimistic cash flow projections.

Latest articles

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

Paranovus Stock Rockets 620% as $195 Million Share-Sale Filing Changes the Story

9 June 2026
Paranovus Entertainment shares soared 620% to $6.76 after filing to potentially sell up to $195 million in new stock—an amount far exceeding its $7.14 million market cap—raising major dilution risks for investors as the company eyes acquisitions but warns that future share sales could pressure the stock price or threaten operations.
Coupang Stock Gains as Privacy Ruling Approaches

Coupang Stock Gains as Privacy Ruling Approaches

9 June 2026
Coupang shares jumped 2% to $15.49, outperforming a falling market, as investors braced for South Korea’s privacy regulator to decide June 10 on possible sanctions over a data breach exposing 33.6 million records—a ruling that could trigger fines up to 3% of sales and impact the stock’s recovery.
AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

AEP’s $78 Billion Grid Plan Spurs Data Center Hopes

9 June 2026
AEP lifted its five-year capital plan to $78 billion after signing 7 gigawatts of new large-energy project agreements, with 90% of 63 gigawatts of expected incremental load by 2030 tied to data centers; shares recently traded at $127.27, up 26.9% over 52 weeks, with analysts’ mean price target at $142.76, as investors weigh execution risks and a new data-center rate structure.
Dow climbs in New York, but gains may stall

Dow climbs in New York, but gains may stall

9 June 2026
Dow jumps 154.87 points as tech rebounds and oil prices drop, with chipmakers like Intel and Broadcom up sharply; investors brace for Wednesday’s key inflation data and next week’s Fed meeting, which could sway rate expectations and market direction.
U.S. Stocks Hit Records This Week — Why the S&P 500 and Nasdaq Rally Survived the Oil Shock

Dow Up While Nasdaq Dips; AI Rally Meets Inflation Data

9 June 2026
Nuvalent soared after GSK agreed to buy the cancer drug developer for $10.6 billion in cash, valuing shares at $124—a 40% premium to Monday’s close—while investors awaited Wednesday’s key inflation data that could impact market direction and tech stock stability.
SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next
Previous Story

SELLAS Life Sciences (SLS) stock jumps on Phase 3 AML trial timing update — what investors watch next

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target
Next Story

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target

Go toTop